The Split Virus Influenza Vaccine rapidly activates immune cells through Fcγ receptors

Vaccine

Volumn 32, Issue 45, 2014, Pages 5989-5997

  O'Gorman, William E ^a   Huang, Huang ^a   Wei, Yu Ling ^a   Davis, Kara L ^a   Leipold, Michael D ^a,b   Bendall, Sean C ^a   Kidd, Brian A ^b   Dekker, Cornelia L ^a   Maecker, Holden T ^a,b   Chien, Yueh Hsiu ^a   Davis, Mark M ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fc receptors; Immunology; Influenza; Mass cytometry; Vaccine

Indexed keywords

ANTIBODY; CYTOKINE; FC RECEPTOR; INFLUENZA PROTEIN; INFLUENZA VACCINE; RESIQUIMOD; SPLIT VIRUS INFLUENZA VACCINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOGLOBULIN G; ISCOM; TLR7 PROTEIN, HUMAN; TLR8 PROTEIN, HUMAN; VIRUS ANTIBODY;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMETRY BY TIME OF FLIGHT; DRUG POTENCY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLUENZA; INFLUENZA VACCINATION; INNATE IMMUNITY; MALE; PROTEIN FUNCTION; PROTEOMICS; SERUM FACTOR; SIGNAL TRANSDUCTION; VIRUS INACTIVATION; AGONISTS; BLOOD; CELL CULTURE; IMMUNOLOGY; INFLUENZA, HUMAN; MONOCYTE;

ADULT; ANTIBODIES, VIRAL; CELLS, CULTURED; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA VACCINES; INFLUENZA, HUMAN; ISCOMS; MALE; MONOCYTES; RECEPTORS, IGG; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84907984229     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.115     Document Type: Article

References (39)

1. World Health Organization WHO|influenza (seasonal) 2009, WHO.
2. Nichol K.L., Treanor J.J. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006, 194(Suppl. 2):S111-S118.
3. Wood J.M., William M.S. History of inactivated influenza vaccines 1998, Blackwell Science, Oxford.
4. Wright P.F., Thompson J., Vaughn W.K., Folland D.S., Sell S.H., Karzon D.T. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis 1977, 136(Suppl.):S731-S741.
5. Hampson A.W. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singap 2008, 37:510-517.
6. Stephenson I., Nicholson K.G., Glück R., Mischler R., Newman R.W., Palache A.M., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362:1959-1966.
7. Geeraedts F., Bungener L., Pool J., Veer ter W., Wilschut J., Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Resp Viruses 2008, 2:41-51.
8. Zhu J., Martinez J., Huang X., Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN. Blood 2007, 109:619-625.
9. Querec T. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006, 203:413-424.
10. Koyama S., Aoshi T., Tanimoto T., Kumagai Y., Kobiyama K., Tougan T., et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med 2010, 2. 25ra24-34.
11. Geeraedts F., Goutagny N., Hornung V., Severa M., de Haan A., Pool J., et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 2008, 4:e1000138.
12. Ato M., Takahashi Y., Fujii H., Hashimoto S.-I., Kaji T., Itamura S., et al. Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis. Vaccine 2013, 31:2184-2190.
13. Jeisy-Scott V., Kim J.H., Davis W.G., Cao W., Katz J.M., Sambhara S. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice. J Virol 2012, 86:10988-10998.
14. Panda A., Qian F., Mohanty S., Van Duin D., Newman F.K., Zhang L., et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010, 184:2518-2527.
15. Obermoser G., Presnell S., Domico K., Xu H., Wang Y., Anguiano E., et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013, 38:831-844.
16. Bendall S.C., Simonds E.F., Qiu P., Amir E.-A.D., Krutzik P.O., Finck R., et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011, 332:687-696.
17. Newell E.W., Sigal N., Bendall S.C., Nolan G.P., Davis M.M. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity 2012, 36:142-152.
18. Cros J., Cagnard N., Woollard K., Patey N., Zhang S.-Y., Senechal B., et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010, 33:375-386.
19. Pang I.K., Iwasaki A. Inflammasomes as mediators of immunity against influenza virus. Trends Immunol 2011, 32:34-41.
20. Wang J.P., Bowen G.N., Padden C., Cerny A., Finberg R.W., Newburger P.E., et al. Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood 2008, 112:2028-2034.
21. Weichhart T., Säemann M.D. The multiple facets of mTOR in immunity. Trends Immunol 2009, 30:218-226.
22. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdörfer B., Giese T., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531-4537.
23. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview. Clin Infect Dis 2009, 29:313-326.
24. Baker H.N., Murphy R., Lopez E., Garcia C. Conversion of a capture ELISA to a Luminex xMAP assay using a multiplex antibody screening method. J Vis Exp 2012, 65:e4084-e4094.
25. Ruvinsky I., Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006, 31:342-348.
26. Hogarth P.M., Pietersz G.A. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012, 11:311-331.
27. Tanaka M., Krutzik S.R., Sieling P.A., Lee D.J., Rea T.H., Modlin R.L. Activation of Fc RI on monocytes triggers differentiation into immature dendritic cells that induce autoreactive T cell responses. J Immunol 2009, 183:2349-2355.
28. Abdel-Motal U.M., Wigglesworth K., Galili U. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. Vaccine 2009, 27:3072-3082.
29. Getahun A., Heyman B. How antibodies act as natural adjuvants. Immunol Lett 2006, 104:38-45.
30. Brady L.J. Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens. Infect Immun 2005, 73:671-678.
31. Hjelm F., Carlsson F., Getahun A., Heyman B. Antibody-mediated regulation of the immune response. Scand J Immunol 2006, 64:177-184.
32. Siegrist C. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21:3406-3412.
33. Kim D., Huey D., Oglesbee M., Niewiesk S. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 2011, 117:6143-6151.
34. Dixon F.J., Jacot-Guillarmod H., McConahey P.J. The effect of passively administered antibody on antibody synthesis. J Exp Med 1967, 125:1119-1135.
35. Crowe J.E., Firestone C.Y., Murphy B.R. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol 2001, 167:3910-3918.
36. Furman D., Jojic V., Kidd B., Shen-Orr S., Price J., Jarrell J., et al. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Mol Syst Biol 2013, 9:1-14.
37. Sasaki S., He X.-S., Holmes T.H., Dekker C.L., Kemble G.W., Arvin A.M., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 2008, 3:e2975.
38. Beyer W.E.P., Palache A.M., Lüchters G., Nauta J., Osterhaus A.D.M.E. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?. Virus Res 2004, 103:125-132.
39. DiazGranados C.A., Denis M., Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 2012, 31:49-57.